

#### ADVANCING INTEGRATED HEALTHCARE

# Safe Effective Efficient Prescribing: A Pharmacy Prescribing Quality Improvement Initiative Care Transformation Collaborative of R.I.

ORIENTATION KICK OFF FEBRUARY 27, 2020

### Proposal Goals

- Provide practices/SOC with an opportunity to select and implement a practice/SOC focus of medication management improvement based on their own identified practice needs;
- Support primary care practice teams/SOC in the identification and implementation
  of data-driven performance improvement action plans to improve the safe, effective
  and efficient medication management of older adults;
- Improve provider and practice team confidence and skills in implementing evidencebased patient engagement and tools for optimizing medication use;
- •Improve <u>patient</u> medication management outcomes through pharmacy practice facilitation support, peer learning opportunities and applied team-based performance improvement;
- Potentially enhance pharmacy scope and standardization of practice though use of collaborative practice agreements, as applicable to the practice selected area of focus;
- Demonstrate the benefit of a pharmacy led quality improvement initiative.

### S.E.E. Measures Addressing Medication Use Among Older Adults (age 50+)

Safe (S)		Effective (	E)	Efficient (C)				
<ul> <li>Avoid chronic use of benzodiazepines/slarelaxants/"Z" drugs above</li> <li>Avoid combined us</li> <li>Avoid NSAIDS if us</li> <li>Avoid anticholinerg</li> <li>Avoid FQs as initial</li> <li>Rx for naloxone if of use</li> <li>Avoid high risk drug</li> <li>If Rx for buprenorpiavoid other Rx opic benzodiazepines</li> </ul>	keletal muscle /barbiturate/any of e of CNS drugs ing anticoagulant ics if dementia antibiotic in elderly hronic Rx opioid gs in the elderly nine for OUD,	>	rence with: Anticoagulants Metformin Antidepressants Cholesterol medication Controller inhalers Antihypertensives Buprenorphine Statin use in diabetes /ARB use in diabetes use of short acting	<ul><li>wit</li><li>Po les</li><li>Ge</li></ul>	re coordination: patients th 5 or less total prescribers lypharmacy: patients with st than 10 unique rxs eneric utilization:  Overall generic util.  rate  Diabetes generic %  Mental health generic % oiding low value drugs e of erythropoietin			

### Participating Practices

- Anchor Medical (multi-site)
- Brown Medicine Warwick
- Care New England Group Pawtucket
- Coastal Medical
- Medical Associates of RI (MARI)
- Providence Community Health Centers
- University Internal Medicine

### Methods

- RI APCD 2018
  - Includes most commercial insurance and Medicare Advantage
  - No FFS Medicare
- Included patients age 50+ years
  - excluded patients with any oncology rx
- Patient attributed to provider group using prescriber NPI
- All measures oriented such that closer to 100% is better score

Baseline Analysis: S.E.E. Measures Applied to 2018 RI APCD

S1a Avoid chronic use of: opioids         93.2         232,894         92.7         -0.5         93.9         0.7         95.1         1.8         94.3         1.0           S S1b Avoid chronic use of: Skeletal muscle relaxants         97.0         232,894         88.3         -1.2         87.8         -1.7         94.4         4.9         90.7         3.0           F S1d Avoid chronic use of: T2" drugs         97.3         232,894         99.5         -0.1         99.6         -0.6         96.6         -0.7         98.0         0.7           E S1a Avoid chronic use of: Barbiturate         99.7         232,894         99.5         -0.1         99.6         -0.1         99.9         0.3         99.7         0.3         83.6         2.3           Y S2a Avoid combined use of any CNS drugs above         97.1         196,364         96.7         -0.4         97.3         0.2         99.4         0.3         98.9         0.2         99.4         0.3         98.9         0.2         99.4         0.0         99.9         0.3         99.0         0.3         99.0         0.3         99.7         0.1         99.3         0.6         0.8         5.8         0.7         9.8         0.2         99.4         0.3         99.9			POPULATION: AGE 50+ EXCLUDING PTS W ONCO RXS				The column "vs RI" is point difference from RI APCD avg								
S1a Avoid chronic use of: opioids         93.2         232,894         92.7         -0.5         93.9         0.7         95.1         1.8         94.3         1.0           S S1b Avoid chronic use of: Selectal muscle relaxants         97.0         232,894         88.3         -1.2         87.8         -1.7         94.4         4.9         90.7         3.0           F S1d Avoid chronic use of: Selectal muscle relaxants         97.0         232,894         99.5         0.2         97.3         0.3         94.1         2.9         97.3         0.3           E S1d Avoid chronic use of: T2" drugs         97.3         232,894         99.5         -0.1         99.6         -0.1         99.9         0.3         99.7         0.3         98.7         0.1         99.6         -0.1         99.9         0.3         99.7         0.3         99.7         0.1         19.6         40.7         79.8         -1.5         48.5         2.2         89.7         13.9         49.9         1.0         99.9         0.3         99.7         0.1         19.6         34.9         1.0         99.9         0.3         99.7         0.1         19.6         34.9         1.0         99.9         0.3         99.7         0.1         99.8			100% is optimal for all measures (higher is better)	2018 RI APCD		SoC1		So	SoC2		SoC3		C4		
S 31b Avoid chronic use of: benzodiazepines         89.5         232,894         88.3         -1.2         87.8         -1.7         94.4         4.9         90.7         1.2           A S1c Avoid chronic use of: skeletal muscle relaxants         97.0         232,894         97.3         0.2         97.3         0.3         94.1         -2.9         97.3         0.3           E S1e Avoid chronic use of: "Z" drugs         97.3         232,894         99.5         -0.1         99.6         -0.1         99.9         0.3         99.7         0.2           I S 14 Avoid chronic use of: any of above         81.3         232,894         79.6         -17         79.8         -15         84.5         3.2         83.6         2.3           Y S2a Avoid combined use of any CNS drugs above         97.1         196,364         98.4         -0.3         98.9         0.2         99.9         0.3         97.9         0.9         93.3         3.6         2.9         97.2         0.1         99.9         0.3         99.0         0.3         99.0         0.3         99.0         0.3         99.0         0.3         99.0         0.3         99.0         0.8         99.0         0.8         99.0         0.8         99.2         0.1 <t< th=""><th></th><th></th><th>DESCRIPTION</th><th>%</th><th>n</th><th>%</th><th>vs RI</th><th>%</th><th>vs RI</th><th>%</th><th>vs RI</th><th>%</th><th>vs RI</th></t<>			DESCRIPTION	%	n	%	vs RI	%	vs RI	%	vs RI	%	vs RI		
A S1c Avoid chronic use of: Skeletal muscle relaxants       97.0       232,894       97.3       0.2       97.3       0.3       94.1       -2.9       97.3       0.3         F S1d Avoid chronic use of: "I'drugs       97.3       232,894       96.9       -0.4       96.7       -0.6       96.6       -0.7       98.0       0.7         T S1f Avoid chronic use of: barbiturate       99.7       232,894       99.5       -1.7       79.8       -1.5       84.5       3.2       83.6       2.3         Y S2a Avoid combined use of any of above       91.1       196,344       96.7       -0.4       97.3       0.2       97.2       0.1       97.9       0.9         S2b Avoid combined use of opioids and benzodiazepines       98.7       196,364       98.4       -0.3       99.9       0.2       99.4       0.8       99.0       2.2       99.4       0.8       99.0       0.3       3.6       85.5       5.4       98.7       196,364       98.4       -0.3       99.9       0.2       99.4       0.8       99.0       0.3       3.6       85.5       8.0       8.7       71.8       -13.3       80.1       1.8       91.8       8.8       95.8       0.2       93.3       0.6       85.7       71.		S1a	Avoid chronic use of: opioids	93.2	232,894	92.7	-0.5	93.9	0.7	95.1	1.8	94.3	1.0		
F S1d Avoid chronic use of: "2" drugs         97.3         232,884         96.9         -0.4         96.7         -0.6         96.6         -0.7         98.0         0.7           E S1E Avoid chronic use of: barbiturate         99.7         232,884         95.5         -0.1         99.6         -0.1         99.9         0.3         99.7         0.1           T S1f Avoid chronic use of: any of above         81.3         232,884         79.6         -1.7         79.8         -1.5         84.5         3.2         83.6         23.8           Y S2a Avoid combined use of oploids and benzodiazepines         98.7         196,364         98.4         -0.3         98.9         0.2         99.4         0.8         99.0         0.3         98.9         0.2         99.4         0.8         99.0         0.3         98.9         0.2         99.4         0.8         99.0         0.3         98.9         0.2         99.4         0.8         99.0         0.3         98.0         0.2         97.2         0.1         99.0         0.3         99.0         0.3         99.0         0.3         99.0         0.3         99.0         0.3         99.0         0.3         99.0         0.3         99.0         0.3         90.0 <th< th=""><th>S</th><th>S1b</th><th>Avoid chronic use of: benzodiazepines</th><th>89.5</th><th>232,894</th><th>88.3</th><th>-1.2</th><th>87.8</th><th>-1.7</th><th>94.4</th><th>4.9</th><th>90.7</th><th>1.2</th></th<>	S	S1b	Avoid chronic use of: benzodiazepines	89.5	232,894	88.3	-1.2	87.8	-1.7	94.4	4.9	90.7	1.2		
E S1e Avoid chronic use of: barbiturate 99.7 232,894 99.5 -0.1 99.6 -0.1 99.9 0.3 99.7 0.1 T S1f Avoid chronic use of: any of above 81.3 232,894 79.6 -1.7 79.8 -1.5 84.5 3.2 83.6 2.3 Y S2a Avoid combined use of any CNS drugs above 97.1 196,364 96.7 -0.4 97.3 0.2 97.2 0.1 97.9 0.8 S2b Avoid combined use of opioids and benzodiazepines 98.7 196,364 98.4 -0.3 98.9 0.2 99.4 0.8 99.0 0.3 S3 Avoid NSAIDS if using anticoagulant 93.9 6,359 94.9 1.0 93.3 -0.6 88.5 -5.4 96.7 2.8 S4 Avoid anticholinergics if dementia 85.0 1,885 91.8 6.8 85.8 0.7 71.8 -13.3 87.0 1.9 S5 Avoid fluoroquinolones as initital antibiotic in elderly 85.3 21,826 85.4 0.0 87.3 1.9 81.7 -3.7 86.8 1.5 S6 Rx for naloxone if chronic Rx opioid use 14.0 15,747 15.7 1.7 19.0 5.0 18.3 4.3 19.2 5.2 97. Avoid high risk drugs in the elderly 91.0 10,978 90.5 -0.5 90.8 -0.2 87.5 -3.5 92.1 1.3 S8 If Rx for buprenorphine for OUD, avoid other Rx opioids 93.6 1,645 86.1 -7.5 85.5 8.0 95.7 2.1 95.8 2.3 S8b If Rx for buprenorphine for OUD, avoid other Rx opioids 93.6 1,645 63.9 13.1 69.9 -7.1 85.9 8.9 70.8 -6.2 E E 1 Adherence with anticoagulants 77.0 1,645 63.9 13.1 69.9 -7.1 85.9 8.9 70.8 -6.2 E E Adherence with anticoagulants 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 1.5 E E 4 Adherence with controller inhalers 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 1.5 E E 4 Adherence with controller inhalers 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 1.5 E E F Adherence with controller inhalers 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 84.9 2.6 E E F Adherence with controller inhalers 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 84.9 2.5 E E F Adherence with controller inhalers 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 84.9 2.6 E E F Adherence with controller inhalers 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 84.9 2.6 E E F Adherence with controller inhalers 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 84.9 2.6 E E F Adherence with controller inhalers 82.3 82.3 83.7 1.5 47.2 -2.6 45.8 -4.0 50.8 1.0 E F Adherence with controller inhalers 93.2 12.8 80.5 93.0 93.0 93.0 93.0 93.0 93.0 93.0 93.0	Α	S1c	Avoid chronic use of: skeletal muscle relaxants	97.0	232,894	97.3	0.2	97.3	0.3	94.1	-2.9	97.3	0.3		
T S1f Avoid chronic use of: any of above 81.3 23,894 79.6 -1.7 79.8 -1.5 84.5 3.2 83.6 2.3 Y S2a Avoid combined use of any CNS drugs above 97.1 196,864 96.7 -0.4 97.3 0.2 97.2 0.1 97.9 0.9 S2b Avoid combined use of opioids and benzodiazepines 98.7 196,864 98.4 -0.3 98.9 0.2 99.4 0.8 99.0 0.3 S3 Avoid NSAIDS if using anticoagulant 93.9 6,339 94.9 1.0 93.3 -0.6 88.5 -5.4 96.7 2.8 S4 Avoid anticholinergics if dementia 85.0 1,885 91.8 6.8 85.8 0.7 71.8 -13.3 87.0 1.9 S5 Avoid fluoroquinolones as initital antibiotic in elderly 85.3 21,826 85.4 0.0 87.3 1.9 81.7 -3.7 86.8 1.5 S6 Rx for naloxone if chronic Rx opioid use 14.0 15,747 15.7 1.7 19.0 5.0 18.3 4.3 19.2 5.7 Avoid high risk drugs in the elderly 91.0 101,978 90.5 -0.5 90.8 -0.2 87.5 -3.5 92.1 11. S8a if Rx for buprenorphine for OUD, avoid other Rx opioids 93.6 1,645 86.1 -7.5 85.5 -8.0 95.7 2.1 95.8 2.3 S8b if Rx for buprenorphine for OUD, avoid other Rx opioids 93.6 1,645 86.1 -7.5 85.5 -8.0 95.7 2.1 95.8 2.3 S8b if Rx for buprenorphine for OUD, avoid benzodiazepines 77.0 1,645 63.9 -13.1 69.9 -7.1 85.9 8.9 70.8 -6.2 E 1 Adherence with metformin 69.9 8,863 72.0 2.0 71.4 1.5 62.1 -7.8 71.1 1.2 F E 3 Adherence with metformin 69.9 8,863 72.0 2.0 71.4 1.5 62.1 -7.8 71.1 1.2 F E 3 Adherence with metformin 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 84.9 2.6 C E 5 Adherence with holesterol medication 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 84.9 2.6 C E 5 Adherence with huptrenorphine/nkx for OUD 86.0 1,328 86.7 0.7 82.6 3.4 92.2 6.2 88.2 2.9 V E 8 Statin use in diabetes 80.1 24,495 80.5 0.4 83.5 3.4 92.2 6.2 88.2 2.9 E E 9 ACEI/ARB use in diabetes 80.1 24,495 80.5 0.4 83.5 3.4 92.2 6.2 88.2 2.9 E F C C Polypharmacy: patients with less than 10 unique rxs 93.2 182,307 91.0 -2.9 93.3 0.1 87.3 -5.9 93.7 0.1 91.7 1.6 84.9 0.0 91.0 91.0 91.0 91.0 91.0 91.0 91.	F	S1d	Avoid chronic use of: "Z" drugs	97.3	232,894	96.9	-0.4	96.7	-0.6	96.6	-0.7	98.0	0.7		
Y S2a Avoid combined use of any CNS drugs above         97.1         196,364         96.7         -0.4         97.3         0.2         97.2         0.1         97.9         0.9           S2b Avoid combined use of opioids and benzodiazepines         98.7         196,364         98.4         -0.3         98.9         0.2         99.4         0.8         99.0         0.3           S3 Avoid NSAIDS if using anticoagulant         93.9         6,359         94.9         1.0         93.3         -0.6         88.5         -5.4         90.2         88.5         -5.4         90.2         88.5         -5.4         90.7         1.8         54         Avoid anticholinergics if dementia         85.0         1.88         85.8         0.7         71.8         -13.3         87.0         1.9         55         Avoid fluoroquinolones as intittal antibiotic in elderly         85.3         21,2826         85.4         0.0         87.3         1.9         81.7         -3.7         86.8         1.5         57         Avoid fligh risk drugs in the elderly         91.0         101,978         90.5         -0.5         90.8         -0.2         87.5         -3.5         92.1         1.1         189.8         95.7         2.1         95.8         2.2         57.5         -3.5	E	S1e	Avoid chronic use of: barbiturate	99.7	232,894	99.5	-0.1	99.6	-0.1	99.9	0.3	99.7	0.1		
S2b         Avoid combined use of opioids and benzodiazepines         98.7         196,364         98.4         -0.3         98.9         0.2         99.4         0.8         99.0         0.3           S3         Avoid NSAIDS if using anticoagulant         93.9         6,359         94.9         1.0         93.3         -0.6         88.5         -5.4         96.7         2.8           S4         Avoid fluoroquinolones as intitial antibiotic in elderly         85.3         21,826         85.4         0.0         87.3         19         81.7         -3.7         86.8         15.5           S6         Rx for naloxone if chronic Rx opioid use         14.0         15,747         15.7         1.7         19.0         5.0         18.3         4.3         19.2         5.2           S7         Avoid high risk drugs in the elderly         91.0         101,978         90.5         -0.5         90.8         -0.2         87.5         -3.5         92.1         1.1           S8b If Rx for buprenorphine for OUD, avoid other Rx opioids         93.6         1,645         63.9         -13.1         69.9         7.7         1,645         63.9         -13.1         69.9         7.7         1,645         63.9         -14.1         1.5         62.1	_		,	81.3	232,894	79.6	-1.7	79.8	-1.5	84.5	3.2	83.6	2.3		
S3         Avoid NSAIDS if using anticoagulant         93.9         6,359         94.9         1.0         93.3         -0.6         88.5         -5.4         96.7         2.8           S4         Avoid anticholinergics if dementia         85.0         1,885         91.8         6.8         85.8         0.7         71.8         -13.3         87.0         1.9           S5         Avoid fluoroquinolones as intittal antibiotic in elderly         85.3         21,826         85.4         0.0         87.3         1.9         81.7         -3.7         86.8         1.5           S6         Rx for naloxone if chronic Rx opioid use         14.0         15,747         1.7         19.0         5.0         18.3         43         19.2         52.2           S7         Avoid high risk drugs in the elderly         91.0         101,978         90.5         -0.5         90.8         -0.2         87.5         -3.5         92.1         11           S8a if Rx for buprenorphine for OUD, avoid benzodiazepines         77.0         1,645         63.9         13.1         69.9         -7.8         6.9         77.1         85.9         8.9         70.8         -0.2           E E1         Adherence with antitiperessants         81.4         40,760	Y	S2a	Avoid combined use of any CNS drugs above	97.1	196,364	96.7	-0.4	97.3	0.2	97.2	0.1	97.9	0.9		
S4         Avoid anticholinergics if dementia         85.0         1,885         91.8         6.8         85.8         0.7         71.8         13.3         87.0         1.9           S5         Avoid fluoroquinolones as initital antibiotic in elderly         85.3         21,826         85.4         0.0         87.3         1.9         81.7         -3.7         86.8         1.5           S6         Rx for naloxone if chronic Rx opioid use         14.0         15,747         15.7         1.7         19.0         50.1         18.3         4.3         19.2         5.2           S7         Avoid high risk drugs in the elderly         91.0         101,978         90.5         -0.5         90.8         -0.2         87.5         -5.9         92.1         1.1           S8b If Rx for buprenorphine for OUD, avoid benzodiazepines         77.0         1,645         63.9         -13.1         69.9         -7.1         85.9         8.9         70.8         -0.2           E E1 Adherence with anticoagulants         73.7         9,596         74.3         0.6         72.8         -0.9         75.6         1.9         73.6         -0.1           F E2 Adherence with anticoagulants         73.7         9,596         74.3         0.6         72.8<		S2b	Avoid combined use of opioids and benzodiazepines	98.7	196,364	98.4	-0.3	98.9	0.2	99.4	0.8	99.0	0.3		
S5         Avoid fluoroquinolones as initital antibiotic in elderly         85.3         21,826         85.4         0.0         87.3         1.9         81.7         -3.7         86.8         1.5           S6         Rx for naloxone if chronic Rx opioid use         14.0         15,747         15.7         1.7         19.0         5.0         18.3         4.3         19.2         5.2           S7         Avoid high risk drugs in the elderly         91.0         101,978         90.5         -0.5         90.8         -0.2         87.5         -3.5         92.1         1.1           S8b If Rx for buprenorphine for OUD, avoid benzodiazepines         77.0         1,645         63.9         -13.1         69.9         7.1         85.9         8.9         70.8         6.2           E E1         Adherence with anticoagulants         73.7         9,596         74.3         0.6         72.8         -0.9         75.6         1.9         73.6         -0.1           F E2         Adherence with metformin         69.9         8,863         72.0         2.0         71.4         1.5         62.1         -7.8         71.1         1.2           E E3         Adherence with anticepressants         81.4         40,760         82.6         1		S3	Avoid NSAIDS if using anticoagulant	93.9	6,359	94.9	1.0	93.3	-0.6	88.5	-5.4	96.7	2.8		
S6         Rx for naloxone if chronic Rx opioid use         14.0         15,747         15.7         1,7         19.0         5.0         18.3         4.3         19.2         5.2           S7         Avoid high risk drugs in the elderly         91.0         101,978         90.5         -0.5         90.8         -0.2         87.5         -3.5         92.1         1.1           S8a         If Rx for buprenorphine for OUD, avoid other Rx opioids         93.6         1,645         86.1         -7.5         85.5         -8.0         95.7         2.1         95.8         2.3           S8b         If Rx for buprenorphine for OUD, avoid benzodiazepines         77.0         1,645         63.9         -13.1         69.9         -7.1         85.9         8.9         70.8         62.2           E E1         Adherence with anticoagulants         73.7         9,596         74.3         0.6         72.8         -0.9         75.6         1.9         73.6         -0.1           F E2         Adherence with metformin         69.9         8,863         72.0         2.0         71.4         1.5         62.1         7.8         71.1         1.2           E E4         Adherence with noticoevith controller inhalers         49.8         9,509		S4	Avoid anticholinergics if dementia	85.0	1,885	91.8	6.8	85.8	0.7	71.8	-13.3	87.0	1.9		
S7         Avoid high risk drugs in the elderly         91.0         101,978         90.5         -0.5         90.8         -0.2         87.5         -3.5         92.1         1.1           S8a If Rx for buprenorphine for OUD, avoid other Rx opioids         93.6         1,645         86.1         -7.5         85.5         -8.0         95.7         2.1         95.8         2.3           S8b If Rx for buprenorphine for OUD, avoid benzodiazepines         77.0         1,645         63.9         -13.1         69.9         -7.1         85.9         8.9         70.8         -6.2           E E1 Adherence with anticoagulants         73.7         9,596         74.3         0.6         72.8         -0.9         75.6         1.9         73.6         -0.1           F E2 Adherence with metformin         69.9         8,863         72.0         2.0         71.4         1.5         62.1         -7.8         1.1         12.2           E E4 Adherence with otholesterol medication         82.3         33,752         83.7         1.4         84.0         1.7         70.0         -12.3         84.9         2.6           C E5 Adherence with controller inhalers         49.8         9,509         48.3         -1.5         47.2         -2.6         45.8		S5	Avoid fluoroquinolones as initital antibiotic in elderly	85.3	21,826	85.4	0.0	87.3	1.9	81.7	-3.7	86.8	1.5		
S8a If Rx for buprenorphine for OUD, avoid other Rx opioids       93.6       1,645       86.1       -7.5       85.5       -8.0       95.7       2.1       95.8       2.3         S8b If Rx for buprenorphine for OUD, avoid benzodiazepines       77.0       1,645       63.9       -13.1       69.9       -7.1       85.9       8.9       70.8       -6.2         E E1 Adherence with anticoagulants       73.7       9,596       74.3       0.6       72.8       -0.9       75.6       1.9       73.6       -0.1         F E2 Adherence with metformin       69.9       8,863       72.0       2.0       71.4       1.5       62.1       -7.8       71.1       1.2         F E3 Adherence with cholesterol medication       82.3       33,752       83.7       1.4       84.0       1.7       70.0       -12.3       84.9       2.6         C E5 Adherence with controller inhalers       49.8       9,509       48.3       -1.5       47.2       -2.6       45.8       -4.0       50.8       1.0         T E6 Adherence with buprenorphine/nlx for OUD       86.0       1,328       86.7       0.7       82.6       -3.4       92.2       6.2       88.2       2.3         V E8 Statin use in diabetes       80.1       24,495		S6	Rx for naloxone if chronic Rx opioid use	14.0	15,747	15.7	1.7	19.0	5.0	18.3	4.3	19.2	5.2		
S8b If Rx for buprenorphine for OUD, avoid benzodiazepines         77.0         1,645         63.9         -13.1         69.9         -7.1         85.9         8.9         70.8         -6.2           E E1 Adherence with anticoagulants         73.7         9,596         74.3         0.6         72.8         -0.9         75.6         1.9         73.6         -0.1           F E2 Adherence with metformin         69.9         8,863         72.0         2.0         71.4         1.5         62.1         -7.8         71.1         1.2           F E3 Adherence with antidepressants         81.4         40,760         82.6         1.2         83.8         2.5         69.5         -11.9         82.9         1.5           E E4 Adherence with cholesterol medication         82.3         33,752         83.7         1.4         84.0         1.7         70.0         -12.3         84.9         2.6           C E5 Adherence with controller inhalers         49.8         9,509         48.3         -1.5         47.2         -2.6         45.8         -4.0         50.8         1.0           T E6 Adherence with antihypertensives         84.2         68,180         85.4         1.2         86.8         2.6         77.9         -6.3         85.4		S7	Avoid high risk drugs in the elderly	91.0	101,978	90.5	-0.5	90.8	-0.2	87.5	-3.5	92.1	1.1		
E E1 Adherence with anticoagulants 73.7 9,596 74.3 0.6 72.8 -0.9 75.6 1.9 73.6 -0.1 F E2 Adherence with metformin 69.9 8,863 72.0 2.0 71.4 1.5 62.1 -7.8 71.1 1.2 F E3 Adherence with antidepressants 81.4 40,760 82.6 1.2 83.8 2.5 69.5 -11.9 82.9 1.5 E E4 Adherence with cholesterol medication 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 84.9 2.6 C E5 Adherence with controller inhalers 49.8 9,509 48.3 -1.5 47.2 -2.6 45.8 -4.0 50.8 1.0 T E6 Adherence with antihypertensives 84.2 68,180 85.4 1.2 86.8 2.6 77.9 -6.3 85.4 1.3 I E7 Adherence with buprenorphine/nlx for OUD 86.0 1,328 86.7 0.7 82.6 -3.4 92.2 6.2 88.2 2.3 V E8 Statin use in diabetes 80.1 24,495 80.5 0.4 83.5 3.4 81.7 1.6 84.3 4.2 E E9 ACEI/ARB use in diabetes 77.5 1,328 76.5 -1.0 79.0 1.5 85.5 81. 78.1 0.7 E10 Use of controller inhalers if multiple rx for inh albuterol 56.8 3,716 47.4 -9.5 64.7 7.8 58.9 2.0 66.3 9.5 E C1 Care coordination: patients with 5 or less total prescribers 93.3 232,894 89.7 -3.6 91.4 -1.9 89.5 -3.7 91.7 -1.6 F C2 Polypharmacy: patients with 185 than 10 unique rxs 93.2 182,307 91.0 -2.2 93.3 0.1 87.3 -5.9 93.7 0.5 F C3 Overall generic utilization rate 89.7 12,986,067 89.5 -0.2 89.5 -0.1 91.6 1.9 88.9 -0.8 I C4 Use of generics: oral antidiabetes medication 81.1 245,199 87.6 6.5 79.7 -1.3 84.6 3.5 82.7 1.7 C C5a Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3 I C5b Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3 I C5b Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3 I C5b Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3 I C5b Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3 I C5b Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3 99.9 0.1 99.9 -0.7 99.9 -0.7 99.9 -0.7 99.9 -0.7 99.9 -0.7 99.9 -0.7 99.9 -0.7 99.9 -0.7 99.9 -0.7 99.9 -0.7 99.9 -0.7		S8a	If Rx for buprenorphine for OUD, avoid other Rx opioids	93.6	1,645	86.1	-7.5	85.5	-8.0	95.7	2.1	95.8	2.3		
F E2         Adherence with metformin         69.9         8,863         72.0         2.0         71.4         1.5         62.1         -7.8         71.1         1.2           F E3         Adherence with antidepressants         81.4         40,760         82.6         1.2         83.8         2.5         69.5         -11.9         82.9         1.5           E E4         Adherence with controller inhalers         49.8         9,509         48.3         -1.5         47.2         -2.6         45.8         -4.0         50.8         1.0           T E6         Adherence with antihypertensives         84.2         68,180         85.4         1.2         86.8         2.6         77.9         -6.3         85.4         1.3           I E7         Adherence with buprenorphine/nlx for OUD         86.0         1,328         86.7         0.7         82.6         -3.4         92.2         6.2         88.2         2.3           V E8         Statin use in diabetes         80.1         24,495         80.5         0.4         83.5         3.4         81.7         1.6         84.3         4.2           E 10         Use of controller inhalers if multiple rx for inh albuterol         56.8         3,716         47.4         -9.5 <th></th> <th>S8b</th> <th>If Rx for buprenorphine for OUD, avoid benzodiazepines</th> <th>77.0</th> <th>1,645</th> <th>63.9</th> <th>-13.1</th> <th>69.9</th> <th>-7.1</th> <th>85.9</th> <th>8.9</th> <th>70.8</th> <th>-6.2</th>		S8b	If Rx for buprenorphine for OUD, avoid benzodiazepines	77.0	1,645	63.9	-13.1	69.9	-7.1	85.9	8.9	70.8	-6.2		
F E3         Adherence with antidepressants         81.4         40,760         82.6         1.2         83.8         2.5         69.5         -11.9         82.9         1.5           E E4         Adherence with cholesterol medication         82.3         33,752         83.7         1.4         84.0         1.7         70.0         -12.3         84.9         2.6           C E5         Adherence with controller inhalers         49.8         9,509         48.3         -1.5         47.2         -2.6         45.8         -4.0         50.8         1.0           T E6         Adherence with antihypertensives         84.2         68,180         85.4         1.2         86.8         2.6         77.9         -6.3         85.4         1.3           I E7         Adherence with buprenorphine/nlx for OUD         86.0         1,328         86.7         0.7         82.6         -3.4         92.2         6.2         88.2         2.3           V E8         Statin use in diabetes         77.5         1,328         76.5         -1.0         79.0         1.5         85.5         8.1         78.1         0.7           E 10         Use of controller inhalers if multiple rx for inh albuterol         56.8         3,716         47.4	E	E1	Adherence with anticoagulants	73.7	9,596	74.3	0.6	72.8	-0.9	75.6	1.9	73.6	-0.1		
E E4 Adherence with cholesterol medication 82.3 33,752 83.7 1.4 84.0 1.7 70.0 -12.3 84.9 2.6 C E5 Adherence with controller inhalers 49.8 9,509 48.3 -1.5 47.2 -2.6 45.8 -4.0 50.8 1.0 T E6 Adherence with antihypertensives 84.2 68,180 85.4 1.2 86.8 2.6 77.9 -6.3 85.4 1.3 I E7 Adherence with buprenorphine/nlx for OUD 86.0 1,328 86.7 0.7 82.6 -3.4 92.2 6.2 88.2 2.3 V E8 Statin use in diabetes 80.1 24,495 80.5 0.4 83.5 3.4 81.7 1.6 84.3 4.2 E E9 ACEI/ARB use in diabetes 77.5 1,328 76.5 -1.0 79.0 1.5 85.5 8.1 78.1 0.7 E10 Use of controller inhalers if multiple rx for inh albuterol 56.8 3,716 47.4 -9.5 64.7 7.8 58.9 2.0 66.3 9.5 E C1 Care coordination: patients with 5 or less total prescribers 93.3 232,894 89.7 -3.6 91.4 -1.9 89.5 -3.7 91.7 -1.6 F C2 Polypharmacy: patients with less than 10 unique rxs 93.2 182,307 91.0 -2.2 93.3 0.1 87.3 -5.9 93.7 0.5 F C3 Overall generic utilization rate 89.7 12,986,067 89.5 -0.2 89.5 -0.1 91.6 1.9 88.9 -0.8 I C4 Use of generics: oral antidiabetes medication 81.1 245,199 87.6 6.5 79.7 -1.3 84.6 3.5 82.7 1.7 C C5a Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3 I C5b Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3 I C5b Use of generics: mental health - antidepressants 98.6 12,986,067 92.9 -2.7 89.3 -6.3 92.9 -2.7 92.9 -2.7 92.9 -2.7 N C7 Avoiding Use of erythropoeitin: rate per 10,000 rxs 95.6 12,986,067 90.9 -4.7 90.9 -4.7 90.9 -4.7 90.9 -4.7	F	E2	Adherence with metformin	69.9	8,863	72.0	2.0	71.4	1.5	62.1	-7.8	71.1	1.2		
C E5 Adherence with controller inhalers	F	E3	Adherence with antidepressants	81.4	40,760	82.6	1.2	83.8	2.5	69.5	-11.9	82.9	1.5		
T E6 Adherence with antihypertensives 84.2 68,180 85.4 1.2 86.8 2.6 77.9 -6.3 85.4 1.3   I E7 Adherence with buprenorphine/nlx for OUD 86.0 1,328 86.7 0.7 82.6 -3.4 92.2 6.2 88.2 2.3   V E8 Statin use in diabetes 80.1 24,495 80.5 0.4 83.5 3.4 81.7 1.6 84.3 4.2   E E9 ACEI/ARB use in diabetes 77.5 1,328 76.5 -1.0 79.0 1.5 85.5 8.1 78.1 0.7   E10 Use of controller inhalers if multiple rx for inh albuterol 56.8 3,716 47.4 -9.5 64.7 7.8 58.9 2.0 66.3 9.5   E C1 Care coordination: patients with 5 or less total prescribers 93.3 232,894 89.7 -3.6 91.4 -1.9 89.5 -3.7 91.7 -1.6   F C2 Polypharmacy: patients with less than 10 unique rxs 93.2 182,307 91.0 -2.2 93.3 0.1 87.3 -5.9 93.7 0.5   F C3 Overall generic utilization rate 89.7 12,986,067 89.5 -0.2 89.5 -0.1 91.6 1.9 88.9 -0.8   I C4 Use of generics: oral antidiabetes medication 81.1 245,199 87.6 6.5 79.7 -1.3 84.6 3.5 82.7 1.7   C C5a Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3   I C5b Use of generics: mental health - antipsychotics 97.4 167,284 97.0 -0.4 97.5 0.1 97.0 -0.3 98.3 0.9   E C6 Avoiding low value drugs: rate per 10,000 rxs 95.6 12,986,067 92.9 -2.7 89.3 -6.3 92.9 -2.7 92.9 -2.7   N C7 Avoiding Use of erythropoeitin: rate per 100,000 rxs 95.7 12,986,067 90.9 -4.7 92.2 -3.5 90.9 -4.7 90.9 -4.7	E	E4	Adherence with cholesterol medication	82.3	33,752	83.7	1.4	84.0	1.7	70.0	-12.3	84.9	2.6		
I E7 Adherence with buprenorphine/nlx for OUD       86.0       1,328       86.7       0.7       82.6       -3.4       92.2       6.2       88.2       2.3         V E8 Statin use in diabetes       80.1       24,495       80.5       0.4       83.5       3.4       81.7       1.6       84.3       4.2         E E9 ACEI/ARB use in diabetes       77.5       1,328       76.5       -1.0       79.0       1.5       85.5       8.1       78.1       0.7         E 10 Use of controller inhalers if multiple rx for inh albuterol       56.8       3,716       47.4       -9.5       64.7       7.8       58.9       2.0       66.3       9.5         E C1 Care coordination: patients with 5 or less total prescribers       93.3       232,894       89.7       -3.6       91.4       -1.9       89.5       -3.7       91.7       -1.6         F C2 Polypharmacy: patients with less than 10 unique rxs       93.2       182,307       91.0       -2.2       93.3       0.1       87.3       -5.9       93.7       0.5         F C3 Overall generic utilization rate       89.7       12,986,067       89.5       -0.2       89.5       -0.1       91.6       1.9       88.9       -0.8         I C4 Use of generics: oral antidiabetes medica	C	E5	Adherence with controller inhalers	49.8	9,509	48.3	-1.5	47.2	-2.6	45.8	-4.0	50.8	1.0		
V E8       Statin use in diabetes       80.1       24,495       80.5       0.4       83.5       3.4       81.7       1.6       84.3       4.2         E E9       ACEI/ARB use in diabetes       77.5       1,328       76.5       -1.0       79.0       1.5       85.5       8.1       78.1       0.7         E 10 Use of controller inhalers if multiple rx for inh albuterol       56.8       3,716       47.4       -9.5       64.7       7.8       58.9       2.0       66.3       9.5         E C1 Care coordination: patients with 5 or less total prescribers       93.3       232,894       89.7       -3.6       91.4       -1.9       89.5       -3.7       91.7       -1.6         F C2 Polypharmacy: patients with less than 10 unique rxs       93.2       182,307       91.0       -2.2       93.3       0.1       87.3       -5.9       93.7       0.5         F C3 Overall generic utilization rate       89.7       12,986,067       89.5       -0.2       89.5       -0.1       88.9       -0.8         I C4 Use of generics: oral antidiabetes medication       81.1       245,199       87.6       6.5       79.7       -1.3       84.6       3.5       82.7       1.7         C C5a Use of generics: mental health - antipsych	Т	E6	Adherence with antihypertensives	84.2	68,180	85.4	1.2	86.8	2.6	77.9	-6.3	85.4	1.3		
E E9 ACEI/ARB use in diabetes 77.5 1,328 76.5 -1.0 79.0 1.5 85.5 8.1 78.1 0.7 E10 Use of controller inhalers if multiple rx for inh albuterol 56.8 3,716 47.4 -9.5 64.7 7.8 58.9 2.0 66.3 9.5 E C1 Care coordination: patients with 5 or less total prescribers 93.3 232,894 89.7 -3.6 91.4 -1.9 89.5 -3.7 91.7 -1.6 F C2 Polypharmacy: patients with less than 10 unique rxs 93.2 182,307 91.0 -2.2 93.3 0.1 87.3 -5.9 93.7 0.5 F C3 Overall generic utilization rate 89.7 12,986,067 89.5 -0.2 89.5 -0.1 91.6 1.9 88.9 -0.8 I C4 Use of generics: oral antidiabetes medication 81.1 245,199 87.6 6.5 79.7 -1.3 84.6 3.5 82.7 1.7 C C5a Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3 I C5b Use of generics: mental health - antipsychotics 97.4 167,284 97.0 -0.4 97.5 0.1 97.0 -0.3 98.3 0.9 E C6 Avoiding low value drugs: rate per 10,000 rxs 95.6 12,986,067 92.9 -2.7 89.3 -6.3 92.9 -2.7 92.9 -2.7 92.9 -2.7 N C7 Avoiding Use of erythropoeitin: rate per 100,000 rxs 95.7 12,986,067 90.9 -4.7 92.2 -3.5 90.9 -4.7 90.9 -4.7	1	E7	Adherence with buprenorphine/nlx for OUD	86.0	1,328	86.7	0.7	82.6	-3.4	92.2	6.2	88.2	2.3		
E10 Use of controller inhalers if multiple rx for inh albuterol 56.8 3,716 47.4 -9.5 64.7 7.8 58.9 2.0 66.3 9.5 E C1 Care coordination: patients with 5 or less total prescribers 93.3 232,894 89.7 -3.6 91.4 -1.9 89.5 -3.7 91.7 -1.6 F C2 Polypharmacy: patients with less than 10 unique rxs 93.2 182,307 91.0 -2.2 93.3 0.1 87.3 -5.9 93.7 0.5 F C3 Overall generic utilization rate 89.7 12,986,067 89.5 -0.2 89.5 -0.1 91.6 1.9 88.9 -0.8 I C4 Use of generics: oral antidiabetes medication 81.1 245,199 87.6 6.5 79.7 -1.3 84.6 3.5 82.7 1.7 C C5a Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3 I C5b Use of generics: mental health - antipsychotics 97.4 167,284 97.0 -0.4 97.5 0.1 97.0 -0.3 98.3 0.9 E C6 Avoiding low value drugs: rate per 10,000 rxs 95.6 12,986,067 92.9 -2.7 89.3 -6.3 92.9 -2.7 92.9 -2.7 92.9 -2.7 90.9 -4.7 90.9 -4.7 90.9 -4.7 90.9 -4.7	٧	E8	Statin use in diabetes	80.1	24,495	80.5	0.4	83.5	3.4	81.7	1.6	84.3	4.2		
E C1 Care coordination: patients with 5 or less total prescribers 93.3 232,894 89.7 -3.6 91.4 -1.9 89.5 -3.7 91.7 -1.6 F C2 Polypharmacy: patients with less than 10 unique rxs 93.2 182,307 91.0 -2.2 93.3 0.1 87.3 -5.9 93.7 0.5 F C3 Overall generic utilization rate 89.7 12,986,067 89.5 -0.2 89.5 -0.1 91.6 1.9 88.9 -0.8 I C4 Use of generics: oral antidiabetes medication 81.1 245,199 87.6 6.5 79.7 -1.3 84.6 3.5 82.7 1.7 C C5a Use of generics: mental health - antidepressants 98.9 784,068 99.0 0.1 98.7 -0.2 99.9 1.0 99.2 0.3 I C5b Use of generics: mental health - antipsychotics 97.4 167,284 97.0 -0.4 97.5 0.1 97.0 -0.3 98.3 0.9 E C6 Avoiding low value drugs: rate per 10,000 rxs 95.6 12,986,067 92.9 -2.7 89.3 -6.3 92.9 -2.7 92.9 -2.7 90.9 -4.7 90.9 -4.7 90.9 -4.7 90.9 -4.7	E	E9	ACEI/ARB use in diabetes	77.5	1,328	76.5	-1.0	79.0	1.5	85.5	8.1	78.1	0.7		
F C2       Polypharmacy: patients with less than 10 unique rxs       93.2       182,307       91.0       -2.2       93.3       0.1       87.3       -5.9       93.7       0.5         F C3       Overall generic utilization rate       89.7       12,986,067       89.5       -0.2       89.5       -0.1       91.6       1.9       88.9       -0.8         I C4       Use of generics: oral antidiabetes medication       81.1       245,199       87.6       6.5       79.7       -1.3       84.6       3.5       82.7       1.7         C C5a       Use of generics: mental health - antidepressants       98.9       784,068       99.0       0.1       98.7       -0.2       99.9       1.0       99.2       0.3         I C5b       Use of generics: mental health - antipsychotics       97.4       167,284       97.0       -0.4       97.5       0.1       97.0       -0.3       98.3       -0.9         E C6       Avoiding low value drugs: rate per 10,000 rxs       95.6       12,986,067       92.9       -2.7       89.3       -6.3       92.9       -2.7       90.9       -4.7         N C7       Avoiding Use of erythropoeitin: rate per 100,000 rxs       95.7       12,986,067       90.9       -4.7       92.2       -3.5 <th></th> <th>E10</th> <th>Use of controller inhalers if multiple rx for inh albuterol</th> <th>56.8</th> <th>3,716</th> <th>47.4</th> <th>-9.5</th> <th>64.7</th> <th>7.8</th> <th>58.9</th> <th>2.0</th> <th>66.3</th> <th>9.5</th>		E10	Use of controller inhalers if multiple rx for inh albuterol	56.8	3,716	47.4	-9.5	64.7	7.8	58.9	2.0	66.3	9.5		
F C3         Overall generic utilization rate         89.7         12,986,067         89.5         -0.2         89.5         -0.1         91.6         1.9         88.9         -0.8           I C4         Use of generics: oral antidiabetes medication         81.1         245,199         87.6         6.5         79.7         -1.3         84.6         3.5         82.7         1.7           C C5a         Use of generics: mental health - antidepressants         98.9         784,068         99.0         0.1         98.7         -0.2         99.9         1.0         99.2         0.3           I C5b         Use of generics: mental health - antipsychotics         97.4         167,284         97.0         -0.4         97.5         0.1         97.0         -0.3         98.3         0.9           E C6         Avoiding low value drugs: rate per 10,000 rxs         95.6         12,986,067         92.9         -2.7         89.3         -6.3         92.9         -2.7           N C7         Avoiding Use of erythropoeitin: rate per 100,000 rxs         95.7         12,986,067         90.9         -4.7         92.2         -3.5         90.9         -4.7	E	C1	Care coordination: patients with 5 or less total prescribers	93.3	232,894	89.7	-3.6	91.4	-1.9	89.5	-3.7	91.7	-1.6		
I C4       Use of generics: oral antidiabetes medication       81.1       245,199       87.6       6.5       79.7       -1.3       84.6       3.5       82.7       1.7         C C5a       Use of generics: mental health - antidepressants       98.9       784,068       99.0       0.1       98.7       -0.2       99.9       1.0       99.2       0.3         I C5b       Use of generics: mental health - antipsychotics       97.4       167,284       97.0       -0.4       97.5       0.1       97.0       -0.3       98.3       0.9         E C6       Avoiding low value drugs: rate per 10,000 rxs       95.6       12,986,067       92.9       -2.7       89.3       -6.3       92.9       -2.7       90.9       -4.7         N C7       Avoiding Use of erythropoeitin: rate per 100,000 rxs       95.7       12,986,067       90.9       -4.7       92.2       -3.5       90.9       -4.7	F	C2	Polypharmacy: patients with less than 10 unique rxs	93.2	182,307	91.0	-2.2	93.3	0.1	87.3	-5.9	93.7	0.5		
C C5a Use of generics: mental health - antidepressants       98.9       784,068       99.0       0.1       98.7       -0.2       99.9       1.0       99.2       0.3         I C5b Use of generics: mental health - antipsychotics       97.4       167,284       97.0       -0.4       97.5       0.1       97.0       -0.3       98.3       0.9         E C6 Avoiding low value drugs: rate per 10,000 rxs       95.6       12,986,067       92.9       -2.7       89.3       -6.3       92.9       -2.7       90.9       -4.7         N C7 Avoiding Use of erythropoeitin: rate per 100,000 rxs       95.7       12,986,067       90.9       -4.7       92.2       -3.5       90.9       -4.7	F	C3	Overall generic utilization rate	89.7	12,986,067	89.5	-0.2	89.5	-0.1	91.6	1.9	88.9	-0.8		
I C5b Use of generics: mental health - antipsychotics       97.4       167,284       97.0       -0.4       97.5       0.1       97.0       -0.3       98.3       0.9         E C6 Avoiding low value drugs: rate per 10,000 rxs       95.6       12,986,067       92.9       -2.7       89.3       -6.3       92.9       -2.7       92.9       -2.7       90.9       -4.7       90.9       -4.7       90.9       -4.7       90.9       -4.7	1	C4	Use of generics: oral antidiabetes medication	81.1	245,199	87.6	6.5	79.7	-1.3	84.6	3.5	82.7	1.7		
E C6 Avoiding low value drugs: rate per 10,000 rxs 95.6 12,986,067 92.9 -2.7 89.3 -6.3 92.9 -2.7 92.9 -2.7 N C7 Avoiding Use of erythropoeitin: rate per 100,000 rxs 95.7 12,986,067 90.9 -4.7 92.2 -3.5 90.9 -4.7 90.9 -4.7	C	C5a	Use of generics: mental health - antidepressants	98.9	784,068	99.0	0.1	98.7	-0.2	99.9	1.0	99.2	0.3		
N C7 Avoiding Use of erythropoeitin: rate per 100,000 rxs 95.7 12,986,067 90.9 -4.7 92.2 -3.5 90.9 -4.7 90.9 -4.7	1			97.4	167,284	97.0	-0.4	97.5	0.1	97.0	-0.3	98.3	0.9		
	E	C6	Avoiding low value drugs: rate per 10,000 rxs	95.6	12,986,067	92.9	-2.7	89.3	-6.3	92.9	-2.7	92.9	-2.7		
-	N	C7	Avoiding Use of erythropoeitin: rate per 100,000 rxs	95.7	12,986,067	90.9	-4.7	92.2	-3.5	90.9	-4.7	90.9	-4.7		
l'	Т														

## Results (highlights)

#### Overall

- Opportunity for improvement (Ofi) exists across all domains
- Variation across systems of care

### Safety

- Ofi: Use of benzodiazepines; Use of any CNS medication; Avoiding FQs; Naloxone co-prescribing
- Positives: Low rate of polytherapy with CNS medications

#### Effectiveness

- Ofi: Adherence; controller inhalers
- Positives: Statin use in DM (?)

### Efficiency

- Ofi: Polypharmacy (approximately 7% of patients w 10+ medications)
- Positives: High use of generic medications in mental health